BMO Capital Initiates Coverage on Retrophin Inc(NASDAQ:RTRX). The shares have been rated Outperform. The rating by BMO Capital was issued on Apr 12, 2016.
Retrophin Inc (RTRX) shares turned negative on Fridays trading session with the shares closing down -0.11 points or -0.71% at a volume of 3,78,719. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $15.58. The peak price level was also seen at $15.58 while the days lowest was $14.985. Finally the shares closed at $15.45. The 52-week high of the shares is $37.04 while the 52-week low is $11.6. According to the latest information available, the market cap of the company is $564 M.
Retrophin Inc(RTRX) last announced its earnings results on Feb 25, 2016 for Fiscal Year 2015 and Q4.Earnings per share were $0.07.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2016, Jeffrey A Meckler (director) purchased 5,000 shares at $15.31 per share price.Also, On Mar 1, 2016, Alvin Shih (EVP of Research & Development) sold 8,750 shares at $14.35 per share price.On Nov 12, 2015, Steve Aselage (Chief Executive Officer) sold 60,000 shares at $18.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.